{"entity":{"id":"nct05023486","kind":"trial","name":"NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies","aka":[],"tldr":"A phase 1/2 trial of NP-G2-044 Monotherapy in advanced solid tumours, run by Novita Pharmaceuticals, Inc., active and no longer recruiting.","summary":"NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies is a phase 1/2 interventional study registered as NCT05023486 by Novita Pharmaceuticals, Inc., with 121 participants enrolled, started 2021-12-07 and due to reach its primary completion in 2026-06-30. Interventions recorded: NP-G2-044 Monotherapy, Anti-PD-1 Therapy and NP-G2-044 Combination therapy.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05023486","url":"https://clinicaltrials.gov/study/NCT05023486"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05023486","phase":"1/2","setting":"NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies","sponsor":"Novita Pharmaceuticals, Inc.","enrolled":121,"outcomes":[]},"route":"/trials/nct05023486/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}